Omada Health
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 week.
- Recent price momentum is -42.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 15.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 52.5x | Better than 9% |
| Forward P/E | 46.1x | Better than 8% |
| Price / Sales | 2.7x | Better than 48% |
| P/E vs own 5-yr range | 81st pctl | Better than 25% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 65.7% | Better than 79% |
| Operating margin | -4.6% | Better than 17% |
| Net margin | -4.9% | Better than 19% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -50.3% | Better than 5% |
| 6-month return | -28.1% | Better than 20% |
| 12-month return (ex latest month) | 2.0% | Better than 36% |
| Distance below 52-week high | 53.4% | Better than 16% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.6x | Better than 78% |
| Debt to assets | 0.0% | Better than 100% |
| Interest coverage | -4.0x | Better than 17% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 88.9% | Better than 71% |
| Upside to average target | 133.1% | Better than 88% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 12.50
- Open
- 12.29
- Day range
- 11.76 - 12.64
- Avg price
- 12.02
- Volume
- 1.71M
- Turnover
- 20.57M
- Turnover ratei
- 3.05%
- Volume ratioi
- 1.20
- Amplitudei
- 7.06%
- 52-week rangei
- 10.28 - 25.45
Valuation
- P/Ei
- -54.20
- P/E (TTM)i
- 52.52
- P/Bi
- 2.70
- EPSi
- -0.22
- Book value / shi
- 4.40
- Net profit
- -13.59M
- Net assets
- 273.15M
Share structure
- Market cap
- 736.39M
- Float capi
- 666.96M
- Shares out
- 62.04M
- Float sharesi
- 56.19M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-06-06
53.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-4.79M net over the window
Short interest
- Shares short
- 9.16M
- % of floati
- 14.97%
- Days to coveri
- 11.38
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Omada Health (OMDA)?
Omada Health last traded at 11.87. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Omada Health's market cap?
About 736.39M.
What is the P/E ratio of Omada Health?
The trailing twelve-month P/E is 52.52. The Valuation tab shows it against the stock's own five-year range.
Does Omada Health pay a dividend?
Omada Health does not currently pay a regular dividend.
Is Omada Health a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 27.67, which implies 133.1% upside from the current price. This is not investment advice.
What is Omada Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Omada Health a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Omada Health discussion 0 comments